GABA for Sleep: Recordings, Ratings and a Conflicting Result

The 300 mg trial measured time to fall asleep

In 2018, researchers randomized 40 adults with insomnia symptoms: 30 to fermented-rice-germ GABA and ten to placebo. They took the assigned tablets for four weeks. The active tablets supplied 300 mg of GABA daily.¹

Overnight recordings showed sleep-onset time falling from 13.4 to 5.7 minutes with GABA, versus rising from 7.0 to 15.2 minutes with placebo. The group-by-time comparison was significant, P=.009.¹

Sleep efficiency and questionnaire scores improved within the GABA group, but those outcomes did not show significant group-by-time benefits. There were only ten placebo participants, and some baseline sleep characteristics differed. Natural Way funded the study and supplied the extract.¹

The 75 mg paper disagrees with its table

The 2022 trial² randomized 54 people; 50 completed four weeks. It tested 75 mg daily against placebo. Recorded sleep-onset time fell from 9.0 to 4.8 minutes with GABA.²

The text says this change was not significant relative to placebo. Table 1 instead lists P=.0240 for the between-group sleep-latency comparison. That unresolved conflict prevents a clean claim that the lower dose either succeeded or failed on that outcome.²

Sleep efficiency did not improve significantly. No adverse events were reported. Natural Way again funded the study and supplied GABA. This was a separate placebo trial, without a simultaneous 300 mg arm; it cannot establish dose equivalence.²

A 2026 exercise study used sleep ratings

A newer randomized, double-blind trial compared 100 mg GABA daily plus home-based exercise with exercise plus placebo for 16 weeks in older women. It reported better Pittsburgh Sleep Quality Index scores with GABA, including sleep-latency and daytime-function ratings.³

Those are questionnaire outcomes, rather than overnight measurements of sleep stages or minutes asleep. We verified the published abstract; it does not provide participant counts or enough numerical results to judge the size of the sleep benefit. The finding applies to GABA added to that exercise program.³

Safety evidence does not supply an indefinite nightly plan

The 2021 USP safety review noted blood-pressure reductions in some studies and a possible added hypotension risk with blood-pressure medicines. It found no pregnancy or lactation studies and very limited interaction research. Ask a pharmacist or clinician about the complete ingredient list, particularly during pregnancy, breastfeeding or treatment for hypertension.⁴

The NHLBI describes cognitive behavioral therapy for insomnia, CBT-I, as the usual first treatment for long-term insomnia, typically lasting six to eight weeks. It also notes that the FDA does not review supplements for safety and effectiveness before marketing.⁵

Keep the sleep problem specific

Bring the bottle and a brief record of time spent trying to fall asleep, repeated waking and next-day effects. Ask which problem the proposed supplement should change and when persistent symptoms need assessment. A blend containing GABA, herbs and other ingredients is another formulation to review.

The “Melatonin and Magnesium” section in Did I Do That in My Sleep? explains why adding several supplements at once obscures benefits and adverse effects. Our CBT-I guide covers the structured treatment discussion for ongoing insomnia.